Send to:

Choose Destination
See comment in PubMed Commons below
Med Arh. 2011;65(3):173-5.

Myeloprolipherative disorder type chronic myeloid leukemia--eosinophilic form.

Author information

  • 1Clinic for Oncology, Hematology and Radiotherapy, Department of Hematology, University Clinical Center Tuzla, Tuzla, Bosnia and Herzegovina' Policlinic for Blood Transfusion, University Clinical Center Tuzla, Tuzla, Bosnia and Herzegovina.


Chronic eosinophilic leukemia (CEL) is a very rare form of leucemia in the western world. Adequate response is seldomly achieved after treatment with corticosteroids, interferon-alfa (INF-alfa) and medications containing hydroxi-urea (Litalir). The study presents a patient with CEL with no initial therapeutic response to the use of corticosteroids, INF-alfa and hydroxy-urea, and with neither clinical nor hematological response. After setting a diagnosis of CEL, patient was ordinated Imatinib (Glivec tabbletes) in a daily dose of 200 mg. Two days afterwards there was an evident withdrawal of subjective and clinical symptoms of disease, and the complete blood count showed significant amendment.

[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Loading ...
    Write to the Help Desk